Nurix Therapeutics Inc

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines for cancer and autoimmune diseases. Its clinical-stage oncology pipeline includes bexobrutideg (NX-5948), a brain-penetrant degrader of Bruton's tyrosine kinase (BTK) being co-developed with Roche across malignant hematology, immunology, and neurology, and NX-1607, an oral inhibitor of CBL-B being evaluated across multiple solid tumor types. The company's autoimmune disease pipeline includes bexobrutideg and clinical-stage degraders of IRAK4 (in collaboration with Gilead) and STAT6 (in collaboration with Sanofi). Nurix maintains strategic collaborations with Roche, Gilead Sciences, Sanofi, and Pfizer, retaining certain options for co-development, co-commercialization, and profit sharing in the United States for multiple drug candidates. The company's AI-integrated discovery engine is designed to tackle virtually any protein class using its ligase expertise in targeted protein degradation. Updated Oct 13, 2026